Research Foundation for Mental Hygiene, Inc.   Report issue

Foundation Phase 2 Phase 3 Phase 4
Founded: Menands NY United States (1987)

Organization Overview

First Clinical Trial
1996
NCT00000317
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Research Foundation for Mental Hygiene, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alcoholism (Phase 3)

Attention Deficit Disorder with Hyperactivity (Phase 1)

Cocaine-Related Disorders (Phase 3)

Cognitive Dysfunction (Phase 4)

Depression (Phase 4)

Depressive Disorder (Phase 4)

Depressive Disorder, Major (Phase 4)

Disease (Phase 2)

Fatigue (Phase 2)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis C (Phase 4)

Lyme Disease (Phase 2)

Marijuana Abuse (Phase 2)

Marijuana Use (Phase 2)

Mental Disorders (Phase 2)

Opioid-Related Disorders (Phase 3)

Psychotic Disorders (Phase 4)

Schizophrenia (Phase 4)

Stress Disorders, Post-Traumatic (Phase 4)

Stress Disorders, Traumatic (Phase 4)

Substance-Related Disorders (Phase 2)

Tobacco Use Disorder (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 24
  • # of Trial APIs: 24